PCSK9抑制剂对ACS患者的降脂疗效分析  

Analysis of the Lipid-lowering Effi cacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome

作　　者：马向利 王琼[1] 刘志强[1] Ma Xiangli;Wang Qiong;Liu Zhiqiang(Department of General Cardiology,The First Affi liated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830000)

机构地区：[1]新疆医科大学第一附属医院综合心脏内科,新疆乌鲁木齐830000

出　　处：《科技与健康》2025年第4期13-16,共4页Technology and Health

摘　　要：心血管疾病是全球居民的首要死亡原因,其中急性冠脉综合征(acute coronary syndrome,ACS)是主要相关疾病。当前,ACS治疗的关键是积极采取有效的手段控制血脂水平,所以应当高度重视患者治疗期间的血脂管理。对前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂的作用机制、疗效和安全性等方面的最新临床研究及进展进行综述,期望为PSCK9抑制剂在临床上的合理应用提供参考。Cardiovascular diseases are the leading cause of death worldwide,and acute coronary syndrome(ACS)is a major related disease.Currently,the key to the treatment of ACS is to actively adopt eff ective measures to control lipid levels,so great importance should be attached to the lipid management of patients during treatment.This article reviews the latest clinical research and progress on the mechanism of action,effi cacy,and safety of proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors,aiming to provide a reference for the rational clinical application of PCSK9 inhibitors.

关 键 词：急性冠脉综合征 PCSK9抑制剂 疗效 

分 类 号：R541.4[医药卫生—心血管疾病]